2,5-Dioxotetrahydro-1H-1-pyrrolyl-6-hydrazinonicotinate | 167639-20-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2,5-Dioxotetrahydro-1H-1-pyrrolyl-6-hydrazinonicotinate
• 英文别名: succinimidyl 6-hydrazinonicotinate；(2,5-Dioxopyrrolidin-1-yl) 6-hydrazinylpyridine-3-carboxylate
• CAS: 167639-20-5
• 化学式: C₁₀H₁₀N₄O₄
• 分子量: 250.214
• InChiKey: XGKCDJAWQUZXSJ-UHFFFAOYSA-N

物化性质

• 沸点：
  397.4±52.0 °C(Predicted)
• 密度：
  1?+-.0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  115
• 氢给体数：
  2
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,5-Dioxotetrahydro-1H-1-pyrrolyl-6-hydrazinonicotinate 、 Gly-Ala-Pro-Gly-4 Hyp-Pro-Tyr 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成
  参考文献：
  名称：

  TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING

  摘要：

  本文揭示了一种有针对性的分子成像探针，由信号成分、具有针对Cx43亲和力的成分和连接剂组成。利用该有针对性的分子成像探针，可以通过成像设备检测，反映与心血管疾病（尤其是心律失常）和肿瘤疾病相关的连接素43（Cx43）的生化变异特征，实现体内分子成像。

  公开号：

  US20150202335A1
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 6-肼基烟酸 在 N,N'-二环己基碳二亚胺 作用下， 以 二甲基亚砜 为溶剂， 反应 3.0h， 生成 2,5-Dioxotetrahydro-1H-1-pyrrolyl-6-hydrazinonicotinate 、 2,5-dioxopyrrolidin-1-yl 6-(2-(6-hydrazineylnicotinoyl)hydrazineyl)nicotinate 、 2,5-dioxopyrrolidin-1-yl 6-(2-(6-(2-(6-hydrazineylnicotinoyl)hydrazineyl)nicotinoyl)hydrazineyl)nicotinate 、 2,5-dioxopyrrolidin-1-yl 6-(2-(6-(2-(6-(2-(6-hydrazineylnicotinoyl)hydrazineyl)nicotinoyl)hydrazineyl)nicotinoyl)hydrazineyl)nicotinate
  参考文献：
  名称：

  A technetium intermediate specifically promotes deprotection of trifluoroacetyl HYNIC during radiolabelling under mild conditions

  摘要：

  三氟乙酰基团保护了亲核性的HYNIC，防止其发生不必要的副反应，同时在温和条件下允许与锝-99m进行放射性标记，因为锝金属配合物中间体能有效且特定地促进去保护反应。

  DOI：

  10.1039/b805110k

文献信息

• CYTOTOXIC AGENTS COMPRISING NEW ANSAMITOCIN DERIVATIVES
  申请人：ImmunoGen, Inc.

  公开号：US20160058882A1

  公开（公告）日：2016-03-03

  New ansamitocin derivatives bearing a linking group are disclosed. Also disclosed are methods for the synthesis of these new ansamitocin derivatives and methods for their linkage to cell-binding agents. The ansamitocin derivative-cell-binding agent conjugates are useful as therapeutic agents, which are delivered specifically to target cells and are cytotoxic. These conjugates display vastly improved therapeutic efficacy in animal tumor models compared to the previously described agents.

  披露了带有连接基团的新型安沙米托辛衍生物。还披露了合成这些新型安沙米托辛衍生物的方法以及它们与细胞结合剂的连接方法。安沙米托辛衍生物-细胞结合剂偶联物作为治疗剂非常有用，它们能特异性地传递到目标细胞并具有细胞毒性。与先前描述的药物相比，这些偶联物在动物肿瘤模型中显示出显著提高的治疗效果。
• Spect Radionuclide-labeled Trimeric Cycle RGD Peptide, Preparation Method Thereof and Imaging Method Thereof
  申请人：Bailing Cloud Biomedical Technologies Innovation

  公开号：US20160235871A1

  公开（公告）日：2016-08-18

  The disclosure is related to a chemical structure, a preparation and an imaging method of a tumor imaging tracer, especially to a SPECT radionuclide-labeled trimeric cyclic RGD peptide: 99m Tc-4P-RGD 3 , which functions as a ligand to be combined with integrin α v β 3 receptor in tumor for tumor imaging. The preparation includes linking HYNIC-OSu with 4P-RGD 3 to form HYNIC-4P-RGD 3 and then chelating HYNIC with 99m Tc to create 99m Tc-4P-RGD 3 . Animal biodistribution and imaging experiments reveal higher uptake in tumor and lower uptake in normal organs, therefore the disclosure can improve image quality, Through animal metabolic experiments, the original form of 99m Tc-4P-RGD 3 can be still excreted without the evidence of further metabolites in urine and feces. According to the disclosure, the tumor imaging tracer 99m Tc-4P-RGD; combined with the integrin α v β 3 solves the issue of high background uptake in normal organs, such that radio-labeled SPECT imaging tracers are more suitable for animal whole-body tumor evaluation.

  该披露涉及化学结构、制备和肿瘤显像示踪剂的成像方法，特别是一种SPECT放射性同位素标记的三聚循环RGD肽：99mTc-4P-RGD3，其作为配体与肿瘤中的整合素αvβ3受体结合用于肿瘤显像。该制备包括将HYNIC-OSu与4P-RGD3连接形成HYNIC-4P-RGD3，然后螯合HYNIC与99mTc形成99mTc-4P-RGD3。动物生物分布和成像实验证实在肿瘤中摄取更高，在正常器官中摄取较低，因此该披露可以提高图像质量。通过动物代谢实验，原始形式的99mTc-4P-RGD3仍可在尿液和粪便中排泄，没有进一步代谢物的证据。根据该披露，肿瘤显像示踪剂99mTc-4P-RGD3与整合素αvβ3结合解决了正常器官中高背景摄取的问题，使放射性标记的SPECT成像示踪剂更适合用于动物全身肿瘤评估。
• COMPOUND HAVING AFFINITY WITH CALCIFIED TISSUE
  申请人：NIHON MEDI-PHYSICS CO., LTD.

  公开号：EP1609797A1

  公开（公告）日：2005-12-28

  The present invention provides a compound excellent in accumulation on calcified tissues and ensuring rapid excretion into urine as well as rapid clearance from blood, useful as a diagnostic agent and a therapeutic agent, etc. The compound is a compound having affinity with a calcified tissue represented by the following formula: (AC)a-MC-(LI)b. In the formula, MC is a mother nucleus and represents a residue of a compound having a plurality of functional groups selected from the group consisting of an amino group, an amide group, a hydroxyl group, a thiol group, a thioether group, a sulfonyl group a phosphonyl group, an aldehyde group, a carboxyl group, a carbonyl group, a halogen, and a cyano group; AC is a group having affinity with a calcified tissue; LI is a ligand for binding to a metal atom; and a is an integer of 1 or more and b is 0 or an integer of 1 or more.

  本发明提供了一种在钙化组织上具有出色积累并确保快速从尿液中排出以及从血液中迅速清除的化合物，可用作诊断剂和治疗剂等。该化合物是与以下公式表示的钙化组织具有亲和力的化合物：(AC)a-MC-(LI)b。在该公式中，MC是母核，表示由多个功能基团中的一种或多种选择组成的残基化合物，该多个功能基团包括氨基、酰胺基、羟基、硫醇基、硫醚基、磺酰基、膦酸基、醛基、羧基、酰基、卤素和氰基；AC是具有钙化组织亲和力的基团；LI是与金属原子结合的配体；a是1或更多的整数，b是0或1或更多的整数。
• Targeted molecular imaging probe and method for in vivo molecular imaging
  申请人：Shen Baozhong

  公开号：US09764048B2

  公开（公告）日：2017-09-19

  Disclosed is a targeted molecular imaging probe consisting of a signal component, a component with a targeted affinity to Cx43 and a linker. The biochemical variation characteristic of connexin43 (Cx43) associated with cardiovascular diseases (especially arrhythmia) and neoplastic diseases can be reflected in the form of an image by using the targeted molecular imaging probe capable of being detected by an imaging device, to achieve in vivo molecular imaging.

  本发明公开了一种靶向分子成像探针，包括信号组分、具有对Cx43的靶向亲和性的组分和连接剂。利用该靶向分子成像探针，可以通过成像设备检测到，反映与心血管疾病（尤其是心律失常）和肿瘤性疾病相关的连接蛋白43（Cx43）的生化变异特征，以实现体内分子成像。
• Protein labelling
  申请人：JOHNSON MATTHEY PUBLIC LIMITED COMPANY

  公开号：EP0384769A2

  公开（公告）日：1990-08-29

  Bifunctional aromatic compounds which are capable of linking metal ions to biologically useful molecules. The bifunctional compounds are characterized as having a hydrazine or hydrazide group and a protein reactive group. The hydrazine or hydrazide group may be protected as a lower alkyl hydrazone. Conjugates of the bifunctional compounds with macromolecules are also described and labelled macromolecules comprised of the conjugates and metal ions are provided. Additionally, a method is provided for forming a labelled macromolecule by reacting a conjugate with a metal species. The compounds and method of this invention are particularly useful in the fields of biology and medicine for imaging and/or therapy.

  双官能芳香族化合物能够将金属离子与生物有用分子连接起来。双官能化合物的特点是具有一个肼或酰肼基团和一个蛋白质活性基团。肼或酰肼基团可作为低级烷基腙加以保护。还描述了双官能团化合物与大分子的共轭物，并提供了由共轭物和金属离子组成的标记大分子。此外，还提供了一种通过共轭物与金属物种反应形成标记大分子的方法。本发明的化合物和方法尤其适用于生物学和医学领域的成像和/或治疗。